OOIR: Observatory of International Research

Papers

(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis	356
A proposal for staging COVID‐19 coagulopathy	76
Venous thromboembolism in critically Ill patients with COVID‐19: Results of a screening study for deep vein thrombosis	73
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality	69
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)	58
Sexism in the management of bleeding disorders	56
Tranexamic acid evidence and controversies: An illustrated review	51
Heparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome	49
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients	47
Thrombosis and coagulopathy in COVID‐19: An illustrated review	46
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study	45
Potential role of platelets in COVID‐19: Implications for thrombosis	40
Comparison of the coagulopathies associated with COVID‐19 and sepsis	39
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis	39
Posters Abstracts	36
Abstract	35
Essential aspects of the follow‐up after acute pulmonary embolism: An illustrated review	35
Anticoagulation practice patterns in COVID‐19: A global survey	34
Abstracts	34
The role of platelets in sepsis	34
Protease‐activated receptors: An illustrated review	33
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries	31
Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19	31
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)	30
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features	30

Hormonal therapies and venous thrombosis: Considerations for prevention and management